1. Home
  2. DCOY vs BRTX Comparison

DCOY vs BRTX Comparison

Compare DCOY & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Decoy Therapeutics Inc. Common Stock

DCOY

Decoy Therapeutics Inc. Common Stock

N/A

Current Price

$1.56

Market Cap

3.2M

Sector

Health Care

ML Signal

N/A

Logo BioRestorative Therapies Inc. (NV)

BRTX

BioRestorative Therapies Inc. (NV)

SELL

Current Price

$2.28

Market Cap

3.1M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
DCOY
BRTX
Founded
N/A
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Managed Health Care
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.2M
3.1M
IPO Year
2014
2015

Fundamental Metrics

Financial Performance
Metric
DCOY
BRTX
Price
$1.56
$2.28
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
★ $160.00
AVG Volume (30 Days)
★ 4.1M
25.1K
Earning Date
11-16-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
N/A
★ $81,000.00
Revenue This Year
N/A
$290.60
Revenue Next Year
$20.42
$64.59
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.53
$0.14
52 Week High
$13.51
$4.10

Technical Indicators

Market Signals
Indicator
DCOY
BRTX
Relative Strength Index (RSI) 29.82 54.32
Support Level $0.61 $0.22
Resistance Level $3.29 $2.93
Average True Range (ATR) 0.69 0.20
MACD -0.10 -0.11
Stochastic Oscillator 0.33 26.15

Price Performance

Historical Comparison
DCOY
BRTX

About DCOY Decoy Therapeutics Inc. Common Stock

Decoy Therapeutics Inc is a pre-clinical stage biotechnology company focused on advancing its pipeline of peptide conjugate therapeutics engineered through its proprietary IMP3ACT platform. The IMP3ACT platform represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning (ML) and artificial intelligence (AI" tools alongside high-speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs. The company manages its business in one operating segment, focused on the discovery and development therapeutics for patients with high, unmet medical needs. Its pipeline programs include: Pan-Coronavirus; and Tripledemic.

About BRTX BioRestorative Therapies Inc. (NV)

BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.

Share on Social Networks: